What is the difference between ACE-031 and GHRP-2?

ACE-031: Soluble decoy receptor for ActRIIB; sequesters myostatin, activin, and GDF-11 to remove multiple brakes on muscle and bone growth simultaneously GHRP-2: Synthetic hexapeptide that stimulates pulsatile growth hormone release from the anterior pituitary by acting on the ghrelin receptor (GHSR-1a).

Is ACE-031 FDA approved?

ACE-031 is investigational and not FDA approved. It is discussed for research and educational purposes only, not as medical guidance.

How is ACE-031 administered in research settings?

In research settings, ACE-031 is typically administered via the subcutaneous or intravenous routes. PeptideBase does not provide dosing or administration instructions.

How is GHRP-2 administered in research settings?

In research settings, GHRP-2 is typically administered via the subcutaneous or intramuscular routes. PeptideBase does not provide dosing or administration instructions.

Home›Research›Compare›ACE-031 vs GHRP-2

Peptide Comparison

ACE-031 vs GHRP-2

Name: ACE-031 vs GHRP-2 — Per-mg Price Comparison
Creator: PeptideBase
License: https://peptidebase.io/terms

ACE-031

ACVR2B-Fc

PerformanceInvestigationalResearch Only

Half-life: ~14 days

4 providers listed

Full ACE-031 profile →

GHRP-2

Growth Hormone Releasing Peptide 2

PerformanceUnder clinical reviewResearch Only

Half-life: 15–60 minutes

42 providers listed

Full GHRP-2 profile →

Bottom line

ACE-031 and GHRP-2 target different goals — ACE-031 for myostatin/activin inhibition, GHRP-2 for potent GH release via GHS-R1a agonism. They're compared here for reference, not as direct substitutes.

Quick Verdict

ACE-031

Half-life

~14 days

GHRP-2

Half-life

15–60 minutes

Different Goals

ACE-031 and GHRP-2 target different goals — ACE-031 for Muscle & Myostatin, GHRP-2 for GH / IGF Axis. They're compared here for reference; there isn't a single “better” choice between them.

Side-by-Side Comparison

ACE-031

GHRP-2

Mechanism Family

Muscle & Myostatin

GH / IGF Axis

Half-life

~14 days

15–60 minutes

FDA Status

investigational

Under clinical review

Admin Routes

subcutaneous, intravenous

subcutaneous, intramuscular

Availability

Research Only

Providers

4 listed

42 listed

FDA Update

—

Under clinical review

Avail. Notes

Activin receptor IIB-Fc fusion (ACVR2B decoy) by Acceleron Pharma. Phase 2 for Duchenne MD halted 2013 due to AEs (epistaxis, telangiectasia). Development discontinued. Previously held IND.

Approved for diagnostic GH stimulation testing in Japan (Kaken Pharma) but NOT FDA-approved. Listed on the FDA Category 2 'significant safety risks' bulk-substances list (503B designation, added September 2023). WADA prohibited. Research chemical in US.

Research Evidence

ACE-031

RCT · 1 key study · most recent 2017

GHRP-2

Cohort study · 2 key studies · most recent 2020

Research Citations

ACE-031

RCT2017 · Muscle & Nerve

Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a rando…

GHRP-2

Cohort2020 · Endocrine Journal

Preoperative growth hormone (GH) peak values during a GH releasing peptide-2 test reflect the severity of hyp…

Review2014 · Neurologia Medico-Chirurgica

Adult growth hormone deficiency: current concepts

About ACE-031

Soluble decoy receptor for ActRIIB; sequesters myostatin, activin, and GDF-11 to remove multiple brakes on muscle and bone growth simultaneously

Research Areas

myostatin/activin inhibitionmuscle mass increasebone density improvement

About GHRP-2

Synthetic hexapeptide that stimulates pulsatile growth hormone release from the anterior pituitary by acting on the ghrelin receptor (GHSR-1a). Commonly stacked with GHRH analogs such as CJC-1295 or Sermorelin to amplify GH output synergistically.

Research Areas

potent GH release via GHS-R1a agonismco-stimulation of cortisol and prolactin (non-selective profile)synergistic GH amplification when combined with GHRH analogsvalidated diagnostic GH stimulation agent (Japan clinical use)

Safety Profile

Information below reflects published research data only — not medical advice. Consult a qualified provider before use.

ACE-031

Reported (Unverified — Pending Clinical Review)

cardiovascular diseasetelangiectasia riskbleeding disorderspregnancy

No established clinical contraindications

GHRP-2

Absolute Contraindications

Under clinical review

Being verified by our medical team before we display contraindications for this peptide.

Suggested Monitoring

IGF-1Fasting glucoseHbA1cCortisolInsulin

GHRP-2 stimulates GH and cortisol release. Research protocols measure IGF-1 for GH axis response and baseline cortisol given the compound's adrenal stimulation. Glucose markers are standard given GH's effect on insulin sensitivity.

Used Together?

GHRP-2

Corticosteroids
Research notes that GHRP-2 stimulates cortisol and ACTH release via the HPA axis. Combined use with corticosteroid medications may affect glucocorticoid regulation. Consult your prescriber before combining.

Price (per mg)

ACE-031

$119.00/mg

$78.70 – $161.50 range

8 vendors

View price index →Find providers →

GHRP-2

$3.90/mg

$2.71 – $5.90 range

17 vendors

View price index →Find providers →

Find Providers

Where to source these peptides

Providers offering

ACE-031

4 listed

Browse directory →

Providers offering

GHRP-2

42 listed

Browse directory →

PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.

Related Comparisons

Browse all peptides →

Educational research tools — not medical advice.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). ACE-031 vs GHRP-2 — Per-mg Price Comparison. Retrieved September 11, 2026, from https://peptidebase.io/peptides/compare/ace-031/ghrp-2

https://peptidebase.io/peptides/compare/ace-031/ghrp-2 Methodology License Download JSON Download CSV